Gland Pharma Ltd

The provided pages from the Gland Pharma Limited transcript do not explicitly mention any current or future fundraising plans through debt or equity. Key points related to investments and financial actions are: - The company is planning capital investments of around INR 2,000 crores over the next 3 years, with about INR 300 crores invested this year and INR 500 crores expected in FY '27. - Investments are focused on expanding capacity including ophthalmic lines, blow-fill-seal technology, and CDMO dedicated equipment. - There is no mention of raising funds through debt or equity for these investments. - No discussions or indications regarding new fundraising activities via debt or equity are noted in the excerpt. Therefore, based on this information, no current or future fundraising plans through debt or equity are disclosed.

- Gland Pharma is planning a total investment of around INR 2,000 crores over the next 3 years, in addition to about INR 300 crores in the current year. - For FY '27, expected capex is approximately INR 500 crores. - Investments include setting up an ophthalmic line with suspension capabilities and adopting blow-fill-seal technology, starting next year. - Some CDMO contracts require dedicated equipment and lines, which are part of the ongoing investments. - The company is also focusing on high-tech CDMO areas like microsphere manufacturing technology and nanotechnology, aiming for higher-value CDMO contracts with better margins. - On the sustainability side, efforts include cost optimization such as increasing batch sizes and investing in solar power plants to reduce power costs. - Cenexi is adding new ampoule lines (one added last year ramping up now and another starting August this year) to increase capacity and revenue.

- Gland Pharma expects a consolidated CAGR of around 15% over the next 4-5 years. - FY '27 revenue target for Cenexi is close to EUR 200 million, with major growth expected post capacity additions in FY '28. - Base business growth is projected at 12-13% annually. - CDMO business forms 46% of revenue, growing robustly at 28%, with an additional $40-$50 million revenue expected from CDMO contracts in FY '27. - Strong growth drivers include a robust CDMO pipeline, RTU bag portfolio, complex injectable suspensions, and sterile API-based complex injectables. - FY '29 is expected to have a significant growth step-up due to launches of a couple of large complex products. - Ophthalmic product line and blow-fill-seal technology investments to begin, supporting future capacity. - New product launches, increased volumes, and expanded GPO contracts continue to drive US market growth.

- Gland Pharma expects a consolidated CAGR of 15% over the next four years. - Base business (excluding Cenexi) is projected to grow at around 12-13% CAGR. - Cenexi targets mid-teen EBITDA margins in the midterm. - FY '27 revenue target for Cenexi is about EUR 200 million with growth mainly from capacity additions ramping up in the following year. - CDMO business is a key growth driver, contributing 46% of total revenue and growing at 23%. - Medium-term visibility includes ~$40-50 million incremental growth from CDMO contracts in FY '27. - Margin improvements are expected through operational efficiency, capacity utilization, and integration of Cenexi. - Adjusted PAT margin improved to 16% for FY '26, up from 12% the previous year, indicating profitability growth potential.

- The management stated it is not possible to quantify the contracted capacity out of the 140 million cartridge capacity since it depends on partner projections that change over time. - All 140 million cartridge capacity is for GLP-1 molecules, but the exact contracted amount is not disclosed. - They expect that within the next 12 months, as partners receive approvals and announce launches, more clarity on contracted volumes will emerge publicly. - The ramp-up and volumes for GLP-1 products are anticipated mainly post-2030 when patents expire in the US. - For now, the company is focusing on exhibit batches, filings, and approvals expected in the latter half of the current year. - The insulin contract signed will utilize part of the capacity until full GLP-1 ramp-up occurs. - No concrete figures on current orderbook or pending orders were shared due to confidentiality and variable factors.